Since it was administered to ex-US President Donald Trump, the Monoclonal Antibody-drug cocktail has gained global attention as a miracle cure for Covid-19, but the initial scientific evidence was insufficient. There were a few studies that demonstrated its efficacy, but no studies on the Delta variant of SARS-CoV-2 were conducted worldwide.
AIG Hospitals along with the Asian Healthcare Foundation, CCMB Hyderabad, and Institute of Life Sciences, successfully proved that Monoclonal Therapy reduces severe disease and death in high-risk individuals infected with the Delta Variant of SARS-CoV-2 by 100%.
The Delta is the worst variant of the SARS-CoV-2 with higher infectivity, is more transmissible, with a diverse set of mutations than any other variant. In India, the second wave of havoc was caused due to Delta. “The results are astonishing and will shape the public health policy for treatment of Covid-19 especially in high-risk individuals, those above 60 years of age or even below with underlying health conditions including diabetes, hypertension, obesity, pregnancy, chronic diseases, all will benefit immensely. We have clearly demonstrated in our research that when given at the right time, Monoclonal Therapy stops the progression of the disease completely,” said Dr D Nageshwar Reddy, Chairman, AIG Hospitals.
